A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Simon Harrison ,Andrew Spencer,Hans C Lee,Shinsuke Iida,Robin Lesley,Parameswaran Hari,Anjali Sharma,Ravi Vij,Suzanne Lentzsch,Sikander Ailawadhi,Prashant Kapoor,Vijay V Upreti,Jonathan L Kaufman,Marc S Raab,Monique C Minnema,Faith E Davies,Deepu Madduri,Alex C Minella ,Jeremy T Larsen ,Yongming Zhao

doi:10.1182/blood-2020-134063

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Simon Harrison , Andrew Spencer + Show 18 more

Open Access

https://doi.org/10.1182/blood-2020-134063

Copy DOI

#Research Funding #Equity Holder In Publicly-traded Company + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.